Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RenalytixRNLXD +0.46%46 Buyback Yield % is -84.16 as of Jul. 18, 2026. GuruFocus rates RNLXD with a GF Score™ of 46/100 and a GF Value™ of $7.34. The stock has 3 warning signs investors should review. Among 273 Healthcare Providers & Services companies, Renalytix ranks worse than 96.7% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Renalytix's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNLXD vs VEEV, BTSG, TEM: Buyback Yield % Comparison
For the Health Information Services subindustry, Renalytix's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renalytix Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Renalytix's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renalytix (RNLXD) has a Buyback Yield % of -84.16 as of Jul. 18, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Renalytix and its competitors. According to the industry distribution chart, Renalytix ranks #264 out of 273 companies in the Healthcare Providers & Services industry, placing it in the top 96.7%.
Is Renalytix's Buyback Yield % too high?
Renalytix's current Buyback Yield % is -84.16. Based on the distribution chart, Renalytix ranks #264 out of 273 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Renalytix has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Renalytix's Buyback Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Renalytix ranks #264 out of 273 companies for Buyback Yield %. This places Renalytix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Renalytix and its competitors. Renalytix's current Buyback Yield % is -84.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Renalytix (RNLXD) has a current Buyback Yield % of -84.16. The stock's GF Value™ is $7.34, compared to a current price of $4.11 — trading 44% below its estimated fair value. The current Buyback Yield % is -84.16. Renalytix's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Renalytix (RNLXD), the current Buyback Yield % is -84.16 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renalytix (RNLXD) Overvalued in 2026?
Based on GuruFocus' analysis, Renalytix stock appears to be undervalued.
The current stock price of $4.11 is trading 44% below its estimated GF Value™ of $7.34.
Key valuation signals for RNLXD:
Buyback Yield %: -84.16
GF Value™: $7.34 vs. price of $4.11 (44% below fair value)
No single metric tells the full story. See the RNLXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
46GF Score
Get the complete analysis for RNLXD
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNLXD has been successfully added to your 
